---
title: "Cardiogen"
canonical_url: https://peptidelibrary.app/library/cardiogen
description: "Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Cardiogen

Cardiogen (also called Heart bioregulator or AEDR) is a khavinson bioregulator. Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.

Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.

Also known as: Heart bioregulator, AEDR.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Khavinson bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis. The supporting literature is principally cell-culture and cytogenetic work from a single group, published largely in Russian-language journals, and has not been replicated in contemporary randomised controlled trials. No specific receptor or characterised signalling pathway has been demonstrated.

Targets: Cardiomyocytes (proposed).

Origin: Synthetic short peptide bioregulator.

## Properties

- Sequence: Ala-Glu-Asp-Arg (AEDR)
- Molecular formula: C18H31N7O9
- Molecular weight: 489.49 g/mol
- Half-life: Not established (limited PK data; primarily research context)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 3
- Latest source: 2010

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009. 2009. Preclinical: animal or lab study. Population: Senescent rats with transplanted M-1 sarcoma. Slower tumour growth with more tumour-cell apoptosis and haemorrhagic necrosis. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/20396706/)
2. The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Adv Gerontol. 2009. 2009. Preclinical: in vitro (cells or tissue). Population: Myocardial explants from 3- and 24-month-old rats. More cell proliferation and lower p53 expression in explants from young and old rats. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/20210190/)
3. Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging. Adv Gerontol. 2010. 2010. Preclinical: in vitro (cells or tissue). Population: Cultured human prostate fibroblasts. Higher expression of CXCL12, WEDC1 and ghrelin in ageing cultures; another peptide (T-38) was the most active. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/20586252/)

## Safety

Side effects: Not well characterized.

Risks: Research-only; Limited evidence.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Cardiogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Cardiogen?

Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.

### How does Cardiogen work?

Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.

### Is Cardiogen FDA approved?

No. Cardiogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Cardiogen?

Reported half-life for Cardiogen is Not established (limited PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Cardiogen?

Cardiogen has the sequence Short peptide complex (exact proprietary sequences not publicly standardized). Its molecular formula is Varies (short peptide fraction complex).

### What peptides are similar to Cardiogen?

Compounds most often compared with Cardiogen include Bonomarlot, Bronchogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [\[Peptidergic regulation of age-related alterations in the cardiovascular system.\] — Adv Gerontol, 2026](https://pubmed.ncbi.nlm.nih.gov/42935327/)
- [Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats — Bull Exp Biol Med, 2009](https://pubmed.ncbi.nlm.nih.gov/20396706/)
- [\[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats\] — Adv Gerontol, 2009](https://pubmed.ncbi.nlm.nih.gov/20210190/)
- [\[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging\] — Adv Gerontol, 2010](https://pubmed.ncbi.nlm.nih.gov/20586252/)
